GT719 injection for moderate to severe autoimmune disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have diagnosed lupus (SLE), inflammatory myositis, or systemic sclerosis that is moderate to severe and not well controlled by standard treatments.
- For lupus: your disease activity score must be at least 8, or at least 6 with certain organ involvement.
- For myositis: you must have positive myositis antibodies and your disease is relapsing, hard to treat, or getting worse.
- For systemic sclerosis: you must have positive SSc-related antibodies and your disease is hard to treat or getting worse.
- You cannot have had certain therapies (like complement inhibitors or live vaccines) within the past few weeks, or have had an organ transplant or prior CAR-T therapy (for another target).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
This trial tests a new treatment called GT801, a type of CAR-T cell therapy, for people with moderate to severe autoimmune diseases that have not responded to standard treatments. It aims to see if GT801 can safely and effectively control the disease.
This early-stage study tests a new cell-based treatment called GT801 for autoimmune diseases that haven't responded well to standard medicines. It aims to see if this approach is safe and helps reduce symptoms in conditions like lupus, vasculitis, and scleroderma.
This study tests a new drug called RXIM002 for people with severe autoimmune diseases that haven't improved with standard treatments. It aims to see if targeting immune cells with the CD19 marker can help control the disease.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Hear when a new Auto Immune Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.